Kristina L. Bajema, R. Wiegand, Kendra M. Cuffe, Sadhna V Patel, R. Iachan, T. Lim, Adam Lee, Davia Moyse, F. Havers, Lee Harding, A. Fry, A. Hall, Kelly Martin, Marjorie Biel, Yangyang Deng, W. Meyer, M. Mathur, Tonja M. Kyle, A. Gundlapalli, N. Thornburg, L. Petersen, C. Edens
JAMA internal medicine, 2020
Key Points Question What proportion of persons across 52 US jurisdictions had detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from July to September 2020? Findings In this repeated, cross-sectional study of 177 919 residual clinical specimens, the estimated percentage of persons in a jurisdiction with detectable SARS-CoV-2 antibodies ranged from fewer than 1% to 23%. Over 4 sampling periods in 42 of 49 jurisdictions with calculated estimates, fewer than 10% of people had detectable SARS-CoV-2 antibodies. Meaning While SARS-CoV-2 antibody prevalence estimates varied widely across jurisdictions, most people in the US did not have evidence of previous SARS-CoV-2 infection.
Cited by 120 publications.
Field of study: Medicine